<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">27094990</PMID>
<DateCompleted>
<Year>2017</Year>
<Month>06</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1878-1810</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>175</Volume>
<PubDate>
<Year>2016</Year>
<Month>09</Month>
</PubDate>
</JournalIssue>
<Title>Translational research : the journal of laboratory and clinical medicine</Title>
<ISOAbbreviation>Transl Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.</ArticleTitle>
<Pagination>
<MedlinePgn>103-115.e4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.trsl.2016.03.017</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1931-5244(16)30001-9</ELocationID>
<Abstract>
<AbstractText>Patients undergoing hematopoietic cell transplantation (HCT) with reduced intensity conditioning (RIC) commonly receive fludarabine. Higher exposure of F-ara-A, the active component of fludarabine, has been associated with a greater risk of nonrelapse mortality (NRM). We sought to develop a model for fludarabine dosing in adult HCT recipients that would allow for precise dose targeting and predict adverse clinical outcomes. We developed a pharmacokinetic model from 87 adults undergoing allogeneic RIC HCT that predicts F-ara-A population clearance (Clpop) accounting for ideal body weight and renal function. We then applied the developed model to an independent cohort of 240 patients to identify whether model predictions were associated with NRM and acute graft versus host disease (GVHD). Renal mechanisms accounted for 35.6% of total F-ara-A Clpop. In the independent cohort, the hazard ratio of NRM at day 100 was significantly higher in patients with predicted F-ara-A clearance (Clpred) &lt;8.50 L/h (P &lt; 0.01) and area under the curve (AUCpred) &gt;6.00 μg × h/mL (P = 0.01). A lower Clpred was also associated with more NRM at month 6 (P = 0.01) and trended toward significance at 12 months (P = 0.05). In multivariate analysis, low fludarabine clearance trended toward higher risk of acute GVHD (P = 0.05). We developed a model that predicts an individual's systemic F-ara-A exposure accounting for kidney function and weight. This model may provide guidance in dosing especially in overweight individuals and those with altered kidney function.</AbstractText>
<CopyrightInformation>Copyright © 2016 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sanghavi</LastName>
<ForeName>Kinjal</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wiseman</LastName>
<ForeName>Anthony</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Baylor College of Medicine, Houston, Tex.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kirstein</LastName>
<ForeName>Mark N</ForeName>
<Initials>MN</Initials>
<AffiliationInfo>
<Affiliation>Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cao</LastName>
<ForeName>Qing</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Biostatistics &amp; Informatics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, Minn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brundage</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jensen</LastName>
<ForeName>Kyle</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rogosheske</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>University of Minnesota Medical Center, Minneapolis, Minn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kurtzweil</LastName>
<ForeName>Andy</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>University of Minnesota Medical Center, Minneapolis, Minn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Long-Boyle</LastName>
<ForeName>Janel</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, Calif.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wagner</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatric Bone Marrow Transplantation, University of Minnesota, Minneapolis, Minn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Warlick</LastName>
<ForeName>Erica D</ForeName>
<Initials>ED</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brunstein</LastName>
<ForeName>Claudio G</ForeName>
<Initials>CG</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Weisdorf</LastName>
<ForeName>Daniel J</ForeName>
<Initials>DJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jacobson</LastName>
<ForeName>Pamala A</ForeName>
<Initials>PA</Initials>
<AffiliationInfo>
<Affiliation>Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minn. Electronic address: jacob117@umn.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P01 CA065493</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 CA077598</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 CA099936</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D064888">Observational Study</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2016</Year>
<Month>03</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Transl Res</MedlineTA>
<NlmUniqueID>101280339</NlmUniqueID>
<ISSNLinking>1878-1810</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>FA2DM6879K</RegistryNumber>
<NameOfSubstance UI="D014740">Vidarabine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>P2K93U8740</RegistryNumber>
<NameOfSubstance UI="C024352">fludarabine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D057285">Precision Medicine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012044">Regression Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019172">Transplantation Conditioning</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014740">Vidarabine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>All authors have read the journal's authorship agreement and policy on disclosure of conflict of interest. None of the authors have any conflicts of interest and all authors approved this publication.</CoiStatement>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2015</Year>
<Month>11</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2016</Year>
<Month>03</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2016</Year>
<Month>03</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2016</Year>
<Month>4</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2016</Year>
<Month>4</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2017</Year>
<Month>6</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">27094990</ArticleId>
<ArticleId IdType="pii">S1931-5244(16)30001-9</ArticleId>
<ArticleId IdType="doi">10.1016/j.trsl.2016.03.017</ArticleId>
<ArticleId IdType="pmc">PMC5003687</ArticleId>
<ArticleId IdType="mid">NIHMS773870</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Semin Oncol. 1990 Oct;17(5 Suppl 8):18-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1699279</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Blood Marrow Transplant. 2011 Mar;17(3):300-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20399878</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Invest. 2002;20(7-8):904-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12449721</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Chim Acta. 1991 Aug 30;200(2-3):95-106</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1723357</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Haematologica. 2012 Dec;97(12):1916-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22773600</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Stem Cells Dev. 2014 Nov 1;23(21):2535-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25072307</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 1990 Nov 15;50(22):7226-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1699658</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2005 Oct 15;106(8):2912-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15994282</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pharmacogenetics. 2003 Jan;13(1):29-38</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12544510</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Blood Marrow Transplant. 2014 May;20(5):600-16</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24462742</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Blood Marrow Transplant. 2014 Jun;20(6):890-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24650678</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Genomics Proteomics. 2011 Sep-Oct;8(5):255-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21980041</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bone Marrow Transplant. 2011 Jan;46(1):20-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20383215</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Drug Metab Dispos. 2013 Mar;41(3):541-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23230131</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Blood Marrow Transplant. 2015 Oct;21(10 ):1783-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26055300</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2009 Aug 15;15(16):5280-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19671874</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Chemother Pharmacol. 2015 Jul;76(1):85-96</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25983023</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Chemother Pharmacol. 2013 Sep;72 (3):607-18</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23907443</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2012 May 1;30(13):1553-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22473167</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Blood Marrow Transplant. 2015 Feb;21(2):357-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25452032</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Hematol. 2016 Jan;95(1):115-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26411736</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nephron. 1976;16(1):31-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1244564</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Pharmacother. 2000 Sep;34(9):1066-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10981254</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Blood Marrow Transplant. 2014 Jul;20(7):908-19</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24565993</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Chemother Pharmacol. 1986;17(3):277-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2427240</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Semin Oncol. 1990 Oct;17(5 Suppl 8):39-48</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1699282</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pharmacotherapy. 1998 Nov-Dec;18(6):1224-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9855320</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Treat Rep. 1986 Oct;70(10):1225-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2428492</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Pharmacol Ther. 2002 May;71(5):334-48</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12011819</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Chemother Pharmacol. 2012 Jan;69(1):263-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21909959</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2003 Aug 1;102(3):820-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12676781</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bone Marrow Transplant. 2014 Apr;49(4):589-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24464143</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bone Marrow Transplant. 2007 Feb;39(4):201-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17211431</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Chemother Pharmacol. 2002 Jul;50(1):37-45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12111110</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pharmacogenomics J. 2012 Oct;12(5):395-403</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21625252</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Blood Marrow Transplant. 2014 Jun;20(6):816-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24582782</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Blood Marrow Transplant. 2012 Nov;18(11):1727-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22766220</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Blood Marrow Transplant. 2008 May;14(5):538-45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18410896</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Cancer. 2014 Jan 21;110(2):304-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24300978</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biopharm Drug Dispos. 2010 Jan;31(1):72-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19862681</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2012 Jun 7;119(23):5591-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22496153</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pharmacotherapy. 2001 May;21(5):528-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11349741</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Hematol. 2016 Mar;91(3):302-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26663096</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>